CTX-4430: Phase I started

Celtaxsys began the double-blind, placebo-controlled, Australian Phase I CTX-4430-HV-001 trial to evaluate single and multiple ascending-doses of once-daily, oral CTX-4430 in 96 healthy volunteers. Ce...